Medical Therapy. Pharmacokinetics and Pharmacology Archives

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study

Toru Iwasa, Ryo Inuzuka, Hiroshi Ono, Yuichiro Sugitani, Hirokuni Yamazawa, Chihiro Hiraishi, Naoki Shiota, Shinichi Tanaka, Chieko Yamamoto, Ken-ichi Kurosaki, Masaru Miura, Satoshi YasukochiNational Cerebral and Cardiovascular Center. University of Tokyo. National Center for Child Health and Development. Japan Community Health Care Organization Kyushu Hospital. Hokkaido University. Nippon Shinyaku Company. Tokyo Metropolitan Children’s Medical Center. […]

Safety and Efficacy of Selexipag for Pediatric Pulmonary Arterial Hypertension in Japanese Patients – An Open-Label Phase 2 Study Read More »

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass

Roberto Chiletti, Sophie H. Fincher, Stephen B. Horton, Giles J. Peek, Paul Checchia, Warwick ButtRoyal Children’s Hospital and University of Melbourne. University of Florida. Texas Children’s Hospital and the Baylor College of Medicine. Australia and United States Canadian Journal of CardiologyCan J Cardiol 2024; DOI: 10.1016/j.cjca.2024.12.027 AbstractNitric oxide (NO) was proclaimed the 1992 “molecule of the

The Role of Nitric oxide in the sweep gas for patients receiving Extracorporeal Membrane Oxygenation or Cardiopulmonary Bypass Read More »

Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension

Lene Nygaard Axelsen, Anne Kümmel, Juan Jose Perez Ruixo, Alberto RussuActelion Pharmaceuticals and Johnson & Johnson, Allschwil. Janssen-Cilag S.p.A.Switzerland, Spain and Italy Clinical Pharmacology and Therapeutics: Pharmacometrics and Systems PharmacologyCPT Pharmacometrics Syst Pharmacol 2024;DOI: 10.1002/psp4.13231 AbstractSelexipag is an oral selective prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension (PAH) in adults. To date,

Population pharmacokinetics of selexipag for dose selection and confirmation in pediatric patients with pulmonary arterial hypertension Read More »

Oxygen saturation targets in neonatal care: A narrative review

Tri C. Nguyen, Rajeshwari Madappa, Heather M. Siefkes, Michelle J. Lim, Kanya Mysore Siddegowda, Satyan LakshminrusimhaKaiser Permanente North California. SIGMA Hospital. University of California Davis Children’s Hospital.United States Early Human DevelopmentEarly Hum Dev 2024; 199:DOI: 10.1016/j.earlhumdev.2024.106134 AbstractOptimal oxygenation requires the delivery of oxygen to meet tissue metabolic demands while minimizing hypoxic pulmonary vasoconstriction and oxygen toxicity.

Oxygen saturation targets in neonatal care: A narrative review Read More »

Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery

Heidi M. Manour, Priya Muralidharan, Don Hayes Jr.University of Arizona. Ohio State University College of Medicine. United States Journal of Aerosol Medicine and Pulmonary Drug DeliveryJ Aerosol Med Pulm Drug Deliv 2024; 37: 202-218 DOI: 10.1089/jamp.2024.29117.mk AbstractAn increasing growth in nanotechnology is evident from the growing number of products approved in the past decade. Nanotechnology can

Inhaled Nanoparticulate Systems: Composition, Manufacture and Aerosol Delivery Read More »

The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met?

Julie Wacker, Raphael Joye, Leon Genecand, Frederic Lador, Maurice BeghettiUniversity Hospitals of Geneva. Switzerland Expert Review of Clinical PharmacologyExpert Rev Clin Pharmacol 2024; DOI: 10.1080/17512433.2024.2396119 AbstractIntroduction: Pediatric pulmonary hypertension is a rare condition. Survival remains poor in the current management era. There is a lack of data regarding the medical management of pediatric pulmonary hypertension and most

The evolution of clinical trials for pediatric pulmonary hypertension: are the needs of patients and their caregivers being met? Read More »

Successful oral midodrine therapy for treatment of refractory postoperative chylothorax in an infant

Shunsuke Nukaga, Fujito Numano, Akihiko SaitohNiigata University Graduate School of Medical and Dental Sciences.Japan Cardiology in the YoungCardiol Young 2024; DOI: 10.1017/S1047951124025046 AbstractRefractory chylothorax, a postoperative complication of CHD, is difficult to manage and sometimes fatal. Herein, we report the case of a 10-month-old infant with 22-mosaic trisomy and a coarctation complex, who developed refractory chylothorax

Successful oral midodrine therapy for treatment of refractory postoperative chylothorax in an infant Read More »